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Introduction
In recent years the biomanufacturing industry has seen significant
improvements in recombinant protein production titers due to
advancements in expression technologies as well as media, feed
and manufacturing process development. However, the standard
methods of recombinant cell line development have remained
relatively unchanged.
Most Biopharma teams introduce their
transgene(s) into Chinese Hamster Ovary (CHO) cells using
mechanical or chemical transfection processes whereby the
transgene is randomly integrated into the genome, often times
resulting in significant heterogeneity within the stable pools.
Individual recombinant CHO cells within the pools can vary greatly
in their growth and productivity profiles, product quality
attributes, and genetic stability.
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Figure 1 – The workflow for generating and screening high expressing clones in the CHOZN®
cell line in order to identify genomic hot spots that are suitable for landing pad development.
This figures shows a schematic of our mAb containing “screening landing pad”.

Figure 7 – A schematic of our GFP Landing Pad donor and the workflow for RMCE
mediated integration into our top clones and pools. We then screen and confirm that the
GFP landing pad is precisely integrated and working at our favorite genomic hot spots.
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Following random integration of a mAb expression cassette (our
screening landing pad) we generated minipools for high throughput
screening. Below we show the expression titers from top minipools
measured in 14Day FB Assays in TPP. We determine the landing pad
copy number by running a duplex ddPCR comparing the number of
droplets that are positive for a landing pad specific amplicon relative
to the number of droplets to a known gene. Each pool and clone is
further analyzed by flow cytometry to ensure that we have a
homogeneous population and expression. We then SCC from the
best minipools and confirm their performance
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Figure 2-6 – Images of the cell line development screening process. Select the best minipools for
high expression titers, low copy number (ddPCR) and homogeneous expression (Flow). The table
represents our top pools that moved forward for cloning (Cell Metric) and further development.
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The top expressing minipools/clones are co-transfected with a GFP landing
pad and Cre to mediate RMCE. The existing screening LP is excised and
the GFP LP is integrated in a targeted manner at the same favorable
genomic sites. We then screen and enrich those RMCE pools to validate
the integration before moving into SCC and eventually commercialization.
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Figure 9 – Representative junction PCR images showing integration of the GFP landing pad and increasing
enrichment of the desired population. Shown here is MP83 (left) and MP7 (right). The jPCR amplicons are
increasing in intensity from left to right as we perform the RMCE transfection, then metabolic selection
followed by FACS enrichment to arrive at a population that is our desired GFP landing pad.

We are currently generating SCC of the GFP landing pad
integrated at our favorite candidate hot spots. They will undergo
further testing and method development to ensure that any
clones we commercialize will retain the high expression, stability
and performance required by the industry. Below is a schematic
of how we hope upstream pharma teams will be able to use our
CHO TI cell line for targeted integration of their GOIs.
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Figure 8 – A schematic of Cre Recombinase Mediated Cassette Exchange (RMCE). The
GFP landing pad donor is co-transfected with Cre mRNA to mediate the excision of the
screening landing pad (mAb) and integration of the GFP landing pad using the
complementary flanking Lox sequences.
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The search for hot spots in CHO began by randomly integrating a
mAb expressing landing pad and screening for pools and clones
that support strong expression from a low copy number. Our
favorite pools and clones then underwent RMCE to integrate a
commercial GFP landing pad at those hot spots. We have used a
combination of flow cytometry and jPCR (Figure 8-9) to confirm
that our GFP landing pad is indeed cleanly integrated at the
desired sites in the respective pools. The images below show
jPCR amplicons that can only occur if the GFP landing pad is
correctly integrated into the landing pad sites.
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After identifying high expressing pools and clones the second step
was to excise the screening mAb sequence and replace it with a
customer ready GFP landing pad using the complementary Cre-Lox
sites engineered into our landing pad donors. We then confirm
that our GFP landing pad is integrated at our respective CHO
genomic hot spots using several screening methods including flow
cytometry and junction PCR over the respective landing pad sites.
We are currently testing our top GFP landing pad containing pools
and clones to ensure that they have retained their initial high
expression and homogenous performance. This poster provides
data of actual landing pad pools that have moved through our
workflow towards the development of a commercial CHO TI cell
line for the expression of recombinant proteins.

Creating High Expressing CHO Clones
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We have taken a 2-step approach to developing a landing pad
enabled CHO cell line. The first step was to identify potential hot
spots in the CHO genome that would support strong expression
levels. We started this effort by introducing a mAb expression
cassette (detailed in column 2) into our existing CHOZN® GS -/cell line by random integration and then screened for clones with
strong and stable expression. Our process was typical of most cell
line development projects but we focused on pools and clones that
had only a single copy of our mAb. It was important to identify
clones with 1 integration site to ensure that the expression levels
and performance characteristics could be attributed to a single
genomic site and would be easier for future targeted integration
efforts.
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In contrast, the ability to integrate transgenes at a single, high
expressing and stable site in the CHO genome may greatly
improve the homogeneity of stable pools and yield clones with
more consistent performance. We are creating a robust cell line
with a ready-to-use landing pad at a stable “hot spot” to and
support biotherapeutic manufacturing and improve cell line
development processes. Our current landing pad design includes
a GFP reporter for easy screening and a puromycin resistance
cassette for metabolic selection. The landing pad is flanked with
Lox sites to enable efficient and targeted integration of any
transgene sequence via Cre Recombinase Mediated Cassette
Exchange (RMCE).
This creates a simple and efficient method for any upstream team
to integrate their recombinant protein sequences into our landing
pad site in a targeted manner using the complementary Lox sites.
Integration at a well characterized CHO genomic site should
improve the performance of pools and clones, shorten
development timelines, and reduce the burden of clone screening
and characterization in comparison to existing methods of random
transgene integration.
We are currently in the process of
screening our top pools and clones to ensure that our landing pad
sites will indeed support robust expression and meet the
expectations of the CHO industry.
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Figure 9 – Images of flow cytometry showing the transition from the
screening landing pad (mAb on Y axis) to our final GFP landing pad
intended for commercialization (GFP on X axis). The left panels show the
expression of the screening landing pad in minipool 83 (top row) and in
minipool 7 (bottom row). The middle panels are a control in which the GFP
landing pad has been transfected without Cre and no RMCE has occurred.
The right panel is GFP LP co-transfected with Cre and RMCE has occurred
in a subset of the population. The cells with the correct RMCE switch of
mAb for GFP are shown in the highlighted green box.
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Summary
Our team is building an improved CHO cell line that will enable the
efficient and targeted integration of transgenes at a landing pad site
that supports strong and stable expression. The use of targeted
integration in upstream cell line development can reduce the
heterogeneity of stable pools and deliver clones with more
consistent expression and performance, shortening development
timelines.
We started by randomly integrating a mAb containing landing pad
into CHO to screen for pools and clones capable of high expression
from a low copy number. Our workflow has yielded a number of
clones with mAb expression >2g/L in fed batch assays. Stability
studies are underway as well as genomic characterization of the
integration sites in our top clones.
We then replaced the screening landing pad with a more regulatory
friendly GFP containing landing pad at those same hot spots in our
top expressing CHO clones. We are currently in the process of
validating and confirming that our GFP landing pad sites are stable,
high expressing, and will meet the expectations of the CHO
manufacturing industry.
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